U.S. Food and Drug Administration–Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Obstetrics and Gynaecology
Reference17 articles.
1. Maintenance poly (ADP-ribose) polymerase inhibitor therapy for ovarian cancer: precision oncology or one size fits all?;Berchuck;J Clin Oncol,2017
2. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer;Secord;Int J Gynecol Cancer,2013
3. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis;Smith;Gynecol Oncol,2015
4. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer;Mirza;N Engl J Med,2016
5. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial;Ledermann;Lancet Oncol,2014
Cited by 29 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Whole exome sequencing-based homologous recombination deficiency test for epithelial ovarian cancer;2024-07-18
2. Associations between pharmaceutical industry payments to physicians and prescription of PARP inhibitors in the United States;Gynecologic Oncology;2024-02
3. HRD related signature 3 predicts clinical outcome in advanced tubo-ovarian high-grade serous carcinoma;Gynecologic Oncology;2024-01
4. Olaparib plus bevacizumab as a first-line maintenance treatment for patients with advanced ovarian cancer by molecular status: an updated PAOLA-1 based cost-effectiveness analysis;Journal of Gynecologic Oncology;2024
5. Association between pharmaceutical industry payments to physicians and prescription of PARP inhibitors in the United States;2023-08-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3